Welcome to LookChem.com Sign In|Join Free
  • or
tert-butyl (E)-3-(4-benzyloxyphenyl)propenoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

691905-29-0

Post Buying Request

691905-29-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

691905-29-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 691905-29-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,1,9,0 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 691905-29:
(8*6)+(7*9)+(6*1)+(5*9)+(4*0)+(3*5)+(2*2)+(1*9)=190
190 % 10 = 0
So 691905-29-0 is a valid CAS Registry Number.

691905-29-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (E)-tert-butyl 3-(4-(benzyloxy)phenyl)acrylate

1.2 Other means of identification

Product number -
Other names tert-butyl 4-benzyloxycinnamate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:691905-29-0 SDS

691905-29-0Relevant academic research and scientific papers

N-heterocycle carbene (NHC)-ligated cyclopalladated N,N- dimethylbenzylamine: A highly active, practical and versatile catalyst for the Heck-Mizoroki reaction

Peh, Guang-Rong,Kantchev, Eric Assen B.,Zhang, Chi,Ying, Jackie Y.

supporting information; experimental part, p. 2110 - 2119 (2009/09/05)

The wide dissemination of catalytic protocols in academic and industrial laboratories is facilitated by the development of catalysts that are not only highly active but also user-friendly, stable to moisture, air and long term storage and easy to prepare on a large scale. Herein we describe a protocol for the Heck-Mizoroki reaction mediated by cyclopalladN-dimethylbenzylamine (dmba) ligated ne, 1,3-bdot;HCl in refluxing acetonitrile in air in the presence of K2CO in iates the H bromides in reagent grade NMP at the 0.1-2 mol% range without the need for rigorous anhydrous techniques or a glovebox, and is active even in air. The catalyst is capable of achieving very high levels of catalytic activity (TON of up to 5.22 × 105) for the coupling of a deactivated arylbromide, p-bromoanisole, with tBu acrylate as a benchmark substrate pair. A wide range of aryl bromides, iodides and, for the first time with a NHC-Pd catalyst, a triflate was coupled with diverse acrylate derivatives (nitrile, tert-butyl ester and amides) and styrene derivatives. The use of excess (>2 equiv.) of the aryl bromide and tert-butyl acrylate leads to mixture of tert-butyl β,β-diarylacrylate and tert-butyl cinnamate derivatives depending on the substitution pattern of the aryl bromide. Electron rich m- and p-substituted arylbromides give the diarylated products exclusively, whereas electron-poor aryl bromides give predominantly mono-arylated products. For o-substituted aryl bromides, no doubly arylated products could be obtained under any conditions. Overall, the active catalyst (IMes-Pd) shows higher activity with electron-rich aryl halides, a marked difference compared with the more commonly used phosphane-Pd or non-ligated Pd catalysts.

Practical Heck-Mizoroki coupling protocol for challenging substrates mediated by an N-heterocyclic carbene-ligated palladacycle

Kantchev, Eric Assen B.,Peh, Guang-Rong,Zhang, Chi,Ying, Jackie Y.

supporting information; experimental part, p. 3949 - 3952 (2009/05/30)

(Chemical Equation Presented) A highly active, N-heterocyclic carbene-palladacycle precatalyst for the Heck-Mizoroki reaction was rationally designed. The complex can be synthesized on a large scale in excellent yield by a novel, one-pot, three-component reaction and is tolerant to air, moisture, and long-term storage. A wide range of challenging substrates is successfully coupled under a simple and user-friendly reaction protocol.

Parallel synthesis of homochiral β-amino acids

Davies, Stephen G.,Mulvaney, Andrew W.,Russell, Angela J.,Smith, Andrew D.

, p. 1554 - 1566 (2008/02/09)

The parallel asymmetric synthesis of an array of 30 β-amino acids of high enantiomeric purity using the conjugate addition of homochiral lithium N-benzyl-N-(α-methylbenzyl)amide as the key step is accomplished. The experimental simplicity and highly practical nature of the protocol is demonstrated by the efficient parallel conversion of 15 α,β-unsaturated esters to both enantiomeric series of the corresponding β-amino acids in high overall yields and selectivities with minimal purification involved in each step of the reaction protocol.

Asymmetric dehydration of β-hydroxy esters via kinetic resolution

Kim, Yongtae,Choi, Eui Ta,Lee, Min Hee,Park, Yong Sun

, p. 2833 - 2835 (2007/10/03)

Catalytic asymmetric dehydration of β-hydroxy esters via kinetic resolution has been investigated. The kinetic resolution of rac-β-hydroxy esters in the presence of prolinol chiral ligand 2a and BrZnCH2CO2t-Bu can provide highly enan

3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES

-

Page/Page column 86-87, (2010/02/12)

The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.

CARBOXAMIDES DERIVATIVES

-

Page 30-31, (2010/02/06)

The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity.Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 691905-29-0